Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C

被引:44
作者
Ferir, Geoffrey [1 ]
Palmer, Kenneth E. [2 ,3 ]
Schols, Dominique [1 ]
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium
[2] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA
[3] Univ Louisville, Sch Med, Owensboro Canc Res Program, James Graham Brown Canc Ctr, Louisville, KY 40292 USA
关键词
Griffithsin; Tenofovir; Maraviroc; Enfuvirtide; Synergy; Combination index; Microbicide; HIV-1 clade C; Glycosylation; PBMCs; IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VITRO; CARBOHYDRATE-BINDING; PEPTIDE INHIBITOR; ENTRY INHIBITOR; RHESUS MACAQUES; INFECTION; MICROBICIDE; POTENT; PREVENTION;
D O I
10.1016/j.virol.2011.07.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Griffithsin (GRFT) is possibly the most potent anti-HIV peptide found in natural sources. Due to its potent and broad-spectrum antiviral activity and unique safety profile it has great potential as topical microbicide component. Here, we evaluated various combinations of GRFT against HIV-1 clade B and clade C isolates in primary peripheral blood mononuclear cells (PBMCs) and in CD4(+) MT-4 cells. In all combinations tested, GRFT showed synergistic activity profile with tenofovir, maraviroc and enfuvirtide based on the median effect principle with combination indices (Cl) varying between 0.34 and 0.79 at the calculated EC95 level. Furthermore, the different glycosylation patterns on the viral envelope of clade B and clade C gp120 had no observable effect on the synergistic interactions. Overall, we can conclude that the evaluated two-drug combination increases their antiviral potency and supports further clinical investigations in pre-exposure prophylaxis for GRFT combinations in the context of HIV-1 clade C infection. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 34 条
[1]   Genital Herpes Has Played a More Important Role than Any Other Sexually Transmitted Infection in Driving HIV Prevalence in Africa [J].
Abu-Raddad, Laith J. ;
Magaret, Amalia S. ;
Celum, Connie ;
Wald, Anna ;
Longini, Ira M., Jr. ;
Self, Steven G. ;
Corey, Lawrence .
PLOS ONE, 2008, 3 (05)
[2]   Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin [J].
Alexandre, Kabamba B. ;
Gray, Elin S. ;
Lambson, Bronwen E. ;
Moore, Penny L. ;
Choge, Isaac A. ;
Mlisana, Koleka ;
Karim, Salim S. Abdool ;
McMahon, James ;
O'Keefe, Barry ;
Chikwamba, Rachel ;
Morris, Lynn .
VIROLOGY, 2010, 402 (01) :187-196
[3]   Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women [J].
Baeten, Jared M. ;
Benki, Sarah ;
Chohan, Vrasha ;
Lavreys, Ludo ;
McClelland, R. Scott ;
Mandaliya, Kishorchandra ;
Ndinya-Achola, Jeckoniah O. ;
Jaoko, Walter ;
Overbaugh, Julie .
AIDS, 2007, 21 (13) :1771-1777
[4]   Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection [J].
Balzarini, J ;
Hatse, S ;
Vermeire, K ;
Princen, K ;
Aquaro, S ;
Perno, CF ;
De Clercq, E ;
Egberink, H ;
Vanden Mooter, G ;
Peumans, W ;
Van Damme, E ;
Schols, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :3858-3870
[5]   Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy [J].
Balzarini, Jan .
NATURE REVIEWS MICROBIOLOGY, 2007, 5 (08) :583-597
[6]   Minireview - Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: Pathogenetic and therapeutic implications [J].
Buonaguro, L. ;
Tornesello, M. L. ;
Buonaguro, F. A. .
JOURNAL OF VIROLOGY, 2007, 81 (19) :10209-10219
[7]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[8]   The HIV-1 Subtype C Epidemic in South America Is Linked to the United Kingdom [J].
de Oliveira, Tulio ;
Pillay, Deenan ;
Gifford, Robert J. .
PLOS ONE, 2010, 5 (02)
[9]   Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers [J].
Doncel, Gustavo F. ;
Clark, Meredith R. .
ANTIVIRAL RESEARCH, 2010, 88 :S10-S18
[10]   Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].
Dorr, P ;
Westby, M ;
Dobbs, S ;
Griffin, P ;
Irvine, B ;
Macartney, M ;
Mori, J ;
Rickett, G ;
Smith-Burchnell, C ;
Napier, C ;
Webster, R ;
Armour, D ;
Price, D ;
Stammen, B ;
Wood, A ;
Perros, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732